BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 21300478)

  • 1. Predicting pelvic lymph node involvement in current-era prostate cancer.
    Rahman S; Cosmatos H; Dave G; Williams S; Tome M
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):906-10. PubMed ID: 21300478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
    Nguyen PL; Chen MH; Hoffman KE; Katz MS; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):104-9. PubMed ID: 19286330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.
    Abdollah F; Cozzarini C; Suardi N; Gallina A; Capitanio U; Bianchi M; Tutolo M; Salonia A; La Macchia M; Di Muzio N; Rigatti P; Montorsi F; Briganti A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):624-9. PubMed ID: 22099031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical versus pathologic staging for prostate adenocarcinoma: how do they correlate?
    Cooke EW; Shrieve DC; Tward JD
    Am J Clin Oncol; 2012 Aug; 35(4):364-8. PubMed ID: 21436673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
    Weckermann D; Goppelt M; Dorn R; Wawroschek F; Harzmann R
    BJU Int; 2006 Jun; 97(6):1173-8. PubMed ID: 16686707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
    DiMarco DS; Zincke H; Sebo TJ; Slezak J; Bergstralh EJ; Blute ML
    J Urol; 2005 Apr; 173(4):1121-5. PubMed ID: 15758719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis.
    Heidenreich A; Varga Z; Von Knobloch R
    J Urol; 2002 Apr; 167(4):1681-6. PubMed ID: 11912387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate.
    Stone NN; Stock RG; Parikh D; Yeghiayan P; Unger P
    J Urol; 1998 Nov; 160(5):1722-6. PubMed ID: 9783940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detecting lymph nodes metastasis in prostate cancer through extended vs. standard laparoscopic pelvic lymphadenectomy.
    Arenas LF; Füllhase C; Boemans P; Fichtner J
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S10-4. PubMed ID: 20094944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Algorithm for selecting men for pelvic lymph node dissection (PLND) during radical prostatectomy based on clinical risk factors in an Australian population.
    Sengupta S; Weerakoon M; Sethi K; Ischia J; Webb DR
    BJU Int; 2012 Apr; 109 Suppl 3():48-51. PubMed ID: 22458494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
    Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
    J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
    Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
    Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extent of pelvic lymph node dissection and the impact of standard template dissection on nomogram prediction of lymph node involvement.
    Godoy G; Chong KT; Cronin A; Vickers A; Laudone V; Touijer K; Guillonneau B; Eastham JA; Scardino PT; Coleman JA
    Eur Urol; 2011 Aug; 60(2):195-201. PubMed ID: 21257258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new formula for prostate cancer lymph node risk.
    Yu JB; Makarov DV; Gross C
    Int J Radiat Oncol Biol Phys; 2011 May; 80(1):69-75. PubMed ID: 20594769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robotic extended pelvic lymphadenectomy for intermediate- and high-risk prostate cancer.
    Yuh BE; Ruel NH; Mejia R; Wilson CM; Wilson TG
    Eur Urol; 2012 May; 61(5):1004-10. PubMed ID: 22366188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of PSA and (pre- postoperative) Gleason in predicting the potential lymphatic involvement in patients with prostatic cancer].
    Gómez Veiga F; Díaz Bermúdez J; Alvarez Castelo L; Lorenzo Patiño MJ; Rodríguez Rivera J; Chantada Abal V; Vázquez Martul E; González Martín M
    Arch Esp Urol; 1997; 50(1):33-9. PubMed ID: 9182486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.